| 0.0001 0 (0%) | 10-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cutting-edge immunotherapies. These novel treatments aim to address a range of serious conditions, including autoimmune disorders, neutropenia, anemia, emerging viral infections, and various cancers. This development is underpinned by a proprietary technological platform engineered to restore the body's immune system balance and re-establish overall physiological homeostasis. The company's therapeutic strategies are designed to directly stimulate patients' immune systems, specifically eliciting antigen-specific killer T-cells and antibodies to activate crucial defenses against inflammatory, infectious, and cancerous diseases. Statera BioPharma's clinical pipeline features programs such as STAT-201 for Crohn's disease, Entolimod for hematological conditions, STAT-401 for pancreatic cancer, and STAT-205 for COVID-19. The company is also actively exploring therapeutic applications for fibromyalgia and multiple sclerosis. Formerly known as Cytocom, Inc., the company officially adopted the name Statera BioPharma, Inc. in September 2021. Its operations are headquartered in Fort Collins, Colorado.
Thu, 01 Oct 2026
Statera Biopharma Inc (OTC: STAB) Share Price, STAB Stock News, STAB Share Price & Updates - Kalkine
Wed, 08 Apr 2026
IOBTQ Stock Price and Chart — OTC:IOBTQ - TradingView
Wed, 12 Feb 2025
Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma - Business Wire
Fri, 10 Nov 2023
Alexander Polinsky Net Worth (2026) - GuruFocus
Fri, 13 Jan 2023
Technical Analysis of Statera Biopharma, Inc. (OTC:STAB) - TradingView
Fri, 13 Jan 2023
STAB Stock Price and Chart — OTC:STAB - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|